Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of SHR0302 Tablets in Healthy Subjects
NCT04712838Phase 1Completed
- Sponsor
- Hengrui
- Start
- Mar 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ivarmacitinib in rheumatoid arthritis (RA), atopic dermatitis (AD), alopecia areata and 1 more (6 arms), sponsored by Hengrui. Primary endpoints: Peak Plasma Concentration, Area Under the Plasma Concentration Versus Time Curve and 1 more. Started Mar 2021; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
rheumatoid arthritis (RA)atopic dermatitis (AD)alopecia areataulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04712838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04712838.